Corcept Therapeutics reported phase III data showing its selective glucocorticoid receptor antagonist relacorilant reduced risk of death by 35% when added to chemotherapy in platinum‑resistant ovarian cancer. The result met overall survival as a second primary endpoint after progression‑free survival and has materially lifted investor sentiment ahead of a pending FDA review. Corcept disclosed the Rosella trial outcomes and company filings indicate a July 11, 2026 PDUFA date for the platinum‑resistant ovarian cancer indication. The dataset follows a prior complete response letter for Cushing syndrome, adding complexity to regulatory interactions but giving oncology momentum. What happened: Positive phase III OS data delivered a major readout for relacorilant and moved the needle on commercial forecasts, with analyst models projecting multi‑hundred‑million to billion‑dollar peak sales. Sources: Corcept disclosures and BioCentury market reporting. Clinical context: relacorilant’s mechanism targets glucocorticoid signaling that can confer chemoresistance.